Viral hepatitis with 1.34 million deaths globally has surpassed all chronic infectious diseases including HIV/AIDS, malaria and tuberculosis, according to a study by Global Burden of Disease.
The study reveals that in 2016, the total deaths caused by viral hepatitis, including liver cancer, acute cases, cirrhosis, hepatitis A, E, B, C and D account for 1.34 million globally, exceeding tuberculosis (1.2 million), HIV/AIDS (1 million) and malaria (719,000).
These staggering death rates occurred despite recent advances in hepatitis C medications that can cure most infections within three months and the availability of highly-effective vaccinations for hepatitis B.
"It's outrageous, but not surprising, that the Global Burden of Disease Report found that deaths related to viral hepatitis have surpassed HIV, TB and malaria" said Charles Gore, President of the World Hepatitis Alliance -- a not-for profit organisation based in London.
"This is largely due to a historic lack of political prioritisation coupled with an absent global funding mechanism," Gore added, in the paper published in the journal the Lancet.
Further, viral hepatitis was found to be amongst the top ten leading global killers which include heart disease, road accidents, Alzheimer's disease, amongst others.
If this trend has to be reversed, immediate action must be taken at both a regional and national level, said the report, while suggesting measures such as scaling up testing and diagnosis.
Viral hepatitis is a highly contagious liver infection caused by the hepatitis A virus and only 5 per cent of people living with the disease are aware of their conditions there are only few noticeable symptoms.
As a result, many people are either misdiagnosed or do not come forward for testing, increasing the chance of infecting others and missing the opportunity to access life-saving treatment.
Reducing hepatitis related deaths by 65 per cent by 2030 is a key component of the World Health Organization's Global Hepatitis Strategy.
The strategy, which was adopted by 194 governments, sets out a list of key targets, which, if achieved, will eliminate viral hepatitis by 2030.
--IANS
rt/vd
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
